The potential for a controlled human infection platform in Singapore
Singapore medical journal
;
: 456-461, 2014.
Article
in English
| WPRIM
| ID: wpr-274205
ABSTRACT
For over 100 years, controlled human infection (CHI) studies have been performed to advance the understanding of the pathogenesis, treatment and prevention of infectious diseases. This methodology has seen a resurgence, as it offers an efficient model for selecting the most promising agents for further development from available candidates. CHI studies are utilised to bridge safety and immunogenicity testing and phase II/III efficacy studies. However, as this platform is not currently utilised in Asia, opportunities to study therapeutics and vaccines for infections that are important in Asia are missed. This review examines the regulatory differences for CHI studies between countries and summarises other regulatory differences in clinical trials as a whole. We found that the regulations that would apply to CHI studies in Singapore closely mirror those in the United Kingdom, and conclude that the regulatory and ethical guidelines in Singapore are compatible with the conduct of CHI studies.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Asia
/
Reference Standards
/
Research Design
/
Singapore
/
Quarantine
/
Communicable Disease Control
/
Epidemiology
/
Communicable Diseases
/
Clinical Trials as Topic
/
Cost-Benefit Analysis
Type of study:
Practice guideline
/
Health economic evaluation
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
/
Europa
Language:
English
Journal:
Singapore medical journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS